Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26757008 | 0.89 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL27409308 | 0.89 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL27409321 | 0.87 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL16222136 | 0.82 | TSHR (0.30) | — | |
| SCHEMBL25511794 | 0.82 | ALDH1A1 (0.49) | ALDH1A1 | |
| SCHEMBL16592004 | 0.77 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL26034544 | 0.77 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2A | |
| SCHEMBL19540837 | 0.76 | TSHR (0.36) | KDM4EMEN1KMT2A | |
| SCHEMBL29293247 | 0.76 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL22508202 | 0.75 | ALDH1A1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123914-A1 | PROCESS FOR MAKING ANTIBODY-DRUG CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| US-10561738-B2 | Immunoconjugates with an intracellularly-cleavable linkage | IMMUNOMEDICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20170266316-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | IMMUNOMEDICS, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10561738-B2 | Immunoconjugates with an intracellularly-cleavable linkage | CD47, CD44, DNPEP | ALDH1A1 1678/4885KDM4E 3801/4885MEN1 1430/4885 |
| US-20170266316-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | CD47, CD44, DNPEP | ALDH1A1 1678/4885KDM4E 3801/4885MEN1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.